Although cures for age-related macular degeneration are elusive, the case for prevention through nutrition looks strong and ...

Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like ...

The global ophthalmic products market is projected to grow at a CAGR of 5-7% over the next 5 years. Rising cases of vision ...

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding ...

StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin ...

Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American ...

Lupin partners with SteinCares to commercialize Ranibizumab in Latin America, aiming to improve retinal care access.

Lupin has signed an agreement with SteinCares for the commercialization of biosimilar ranibizumab in Latin America, excluding ...

Lupin has entered into a licence agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin ...

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial ...